# Savara Shares Fall 18% After Company Says FDA Will Miss Molgramostim Action Date

By Riza Dagoc

Canonical URL: https://www.tokenpost.com/news/regulation/62206
Published: 2026-11-20T16:45:29.000Z
Updated: 2026-11-20T16:45:29.000Z
Section: Regulation

> The FDA’s review is ongoing, and the agency has not provided a new action date.

Savara Inc. shares fell about 18% in Friday morning trading after the company said the FDA will not meet the Nov. 22 action date for its molgramostim application.

The FDA’s review is ongoing, and no new action date has been provided. The application is for molgramostim inhalation solution, a treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease.

Molgramostim inhalation solution is a recombinant human granulocyte-macrophage colony-stimulating factor.


